SecSonar.com

Novartis AG (NVS)

Novartis AG at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Novartis AG (NVS) is a Drug Manufacturers - General company based in CH with a market capitalization of $287.1B. Revenue grew 6.0% year-over-year and the company generated $17.7B in free cash flow. This page tracks NVS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CH · 75.88K employees · IPO Nov 7, 1996

Valuation

Valuation & price

$159.90 · as of Jul 4, 2026 · -5.2% vs 52w high

22.2

P/E ratio

Latest-FY diluted EPS

6.22

P/B ratio

Market cap ÷ book equity

2.94%

Dividend yield

Latest fiscal year

Price — last 12 months

$167$140$114Jul 25Dec 25Jul 26Jul 7, 25$122.12Jul 9, 25$122.94Jul 11, 25$121.02Jul 15, 25$119.67Jul 17, 25$114.52Jul 21, 25$114.14Jul 23, 25$117.97Jul 25, 25$117.70Jul 29, 25$117.22Jul 31, 25$113.74Aug 4, 25$117.83Aug 6, 25$113.50Aug 11, 25$118.55Aug 13, 25$121.20Aug 15, 25$124.21Aug 19, 25$124.95Aug 21, 25$126.82Aug 25, 25$125.04Aug 27, 25$126.89Aug 29, 25$126.55Sep 3, 25$128.23Sep 5, 25$129.73Sep 9, 25$128.05Sep 11, 25$127.70Sep 16, 25$122.78Sep 18, 25$122.29Sep 22, 25$123.36Sep 24, 25$123.00Sep 26, 25$123.65Sep 30, 25$128.24Oct 2, 25$130.97Oct 6, 25$132.25Oct 8, 25$132.31Oct 10, 25$130.03Oct 14, 25$130.26Oct 16, 25$130.77Oct 21, 25$131.34Oct 23, 25$131.64Oct 27, 25$129.14Oct 29, 25$121.80Oct 31, 25$123.79Nov 4, 25$125.01Nov 6, 25$126.57Nov 10, 25$127.20Nov 12, 25$132.29Nov 14, 25$131.26Nov 18, 25$128.01Nov 20, 25$124.36Nov 25, 25$130.26Nov 28, 25$130.40Dec 2, 25$132.28Dec 4, 25$132.43Dec 8, 25$130.17Dec 10, 25$131.19Dec 12, 25$132.57Dec 16, 25$135.03Dec 18, 25$135.27Dec 22, 25$136.87Dec 24, 25$138.88Dec 29, 25$139.20Jan 2, 26$138.54Jan 6, 26$142.27Jan 8, 26$141.46Jan 12, 26$141.82Jan 14, 26$146.16Jan 16, 26$144.34Jan 21, 26$145.11Jan 23, 26$147.14Jan 27, 26$152.22Jan 29, 26$148.91Feb 2, 26$151.04Feb 4, 26$152.91Feb 9, 26$157.05Feb 11, 26$160.06Feb 13, 26$163.10Feb 18, 26$165.38Feb 20, 26$162.67Feb 24, 26$167.11Feb 26, 26$165.51Mar 2, 26$166.87Mar 4, 26$165.15Mar 6, 26$160.12Mar 10, 26$161.59Mar 12, 26$154.25Mar 17, 26$154.85Mar 19, 26$148.19Mar 23, 26$148.09Mar 25, 26$150.75Mar 27, 26$148.18Mar 31, 26$152.75Apr 2, 26$154.03Apr 7, 26$151.22Apr 9, 26$155.06Apr 13, 26$154.47Apr 15, 26$152.08Apr 17, 26$151.97Apr 22, 26$147.32Apr 24, 26$145.47Apr 28, 26$145.50Apr 30, 26$147.85May 4, 26$144.62May 6, 26$148.36May 8, 26$146.03May 12, 26$148.16May 14, 26$149.77May 18, 26$149.15May 20, 26$150.45May 22, 26$152.01May 28, 26$151.40Jun 1, 26$145.68Jun 3, 26$143.66Jun 5, 26$149.16Jun 9, 26$149.12Jun 11, 26$153.92Jun 15, 26$151.56Jun 17, 26$150.88Jun 22, 26$148.93Jun 24, 26$153.17Jun 26, 26$155.41Jul 2, 26$159.90
$113.5052-week range$168.62
Loading valuation history…

Fundamentals

Key fundamentals

$287.1B

Market cap

6.0%

Revenue growth (YoY)

75.0%

Gross margin

$17.7B

Free cash flow (USD)

$25.4B

Net debt

-3.9%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$49.4BFY 2017$43.4BFY 2018$46.1BFY 2019$48.7BFY 2020$49.9BFY 2021$44.0BFY 2022$43.5BFY 2023$46.7BFY 2024$51.7BFY 2025$54.8B
$49.4B$54.8B

Free cash flow by year

2016 → 2025

FY 2016$8.6BFY 2017$9.9BFY 2018$10.9BFY 2019$11.4BFY 2020$11.1BFY 2021$12.5BFY 2022$12.0BFY 2023$11.7BFY 2024$13.8BFY 2025$17.7B
$8.6B$17.7B

Gross margin by year

2021 → 2025

FY 202173.3%FY 202273.3%FY 202373.3%FY 202475.2%FY 202575.0%
73.3%75.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Annual reportAnnual Report FiledJun 11, 2026Filing
  • Annual reportAnnual Report FiledApr 28, 2026Filing

Questions

Frequently asked questions

What is Novartis AG's market cap?

Novartis AG (NVS) has a market capitalization of $287.1B.

What is NVS's P/E ratio?

NVS trades at a price-to-earnings ratio of 22.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is NVS's price-to-book (P/B) ratio?

NVS trades at 6.22 times book value per share.

Does Novartis AG pay a dividend?

Yes — NVS paid roughly $4.05 per share in dividends over its latest fiscal year, a yield of about 2.94%.

Are insiders buying NVS stock?

SEC Form 4 filings show no open-market insider buys at Novartis AG in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - General

AZN

AstraZeneca PLC

$288.5B

MRK

Merck & Co., Inc.

$293.4B

ABBV

AbbVie Inc.

$382B

AMGN

Amgen Inc.

$180.9B

GILD

Gilead Sciences, Inc.

$167.4B

PFE

Pfizer Inc.

$148.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.